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a biological context.[1] Biomorphic engi-
neering is a design strategy that attempts 
to develop particles with characteristics 
derived from naturally occurring objects, 
with the aim to attain structures that 
function harmoniously in a living envi-
ronment.[2] As a biological archetype, 
red blood cells (RBCs) possess unique 
morphological features, such as high 
encapsulation of oxygen-storage proteins 
(hemoglobin, Hb) and a discoidal (oblate) 
form with a nonimmunogenic surface 
that facilitates sustained circulation of 
these cells in the cardiovascular system.[3] 
Mimicking RBCs is an excellent strategy 
for developing biomorphic therapeutic 
nanosystems that will be capable of func-
tioning in vivo without the commonly 
encountered problems of reduced circula-
tion and toxicity.[4]
The most significant challenge in 
the development of RBC-mimetic nano-
systems is the engineering of topologi-
cally discrete discoidal particles that retain 
sufficient versatility to enable function-
alization. Recently, we have demonstrated 
that morphological control over the self-
assembly of block copolymeric vesicles 
(polymersomes) can be achieved through a combination of 
molecular engineering and controlled hypertonic shock.[5] 
With this technology, we can produce nanoscopic, biodegrad-
able poly(ethylene glycol)-block-poly(D,L-lactide) (PEG-PDLLA) 
Morphologically discrete nanoarchitectures, which mimic the structural 
complexity of biological systems, are an increasingly popular design 
paradigm in the development of new nanomedical technologies. Herein, 
engineered polymeric stomatocytes are presented as a structural and 
functional mimic of red blood cells (RBCs) with multifunctional therapeutic 
features. Stomatocytes, comprising biodegradable poly(ethylene glycol)-
block-poly(D,L-lactide), possess an oblate-like morphology reminiscent of 
RBCs. This unique dual-compartmentalized structure is augmented via 
encapsulation of multifunctional cargo (oxygen-binding hemoglobin and 
the photosensitizer chlorin e6). Furthermore, stomatocytes are decorated 
with a cell membrane isolated from erythrocytes to ensure that the surface 
characteristics matched those of RBCs. In vivo biodistribution data reveal 
that both the uncoated and coated nano-RBCs have long circulation times 
in mice, with the membrane-coated ones outperforming the uncoated 
stomatoctyes. The capacity of nano-RBCs to transport oxygen and create 
oxygen radicals upon exposure to light is effectively explored toward photo-
dynamic therapy, using 2D and 3D tumor models; addressing the challenge 
presented by cancer-induced hypoxia. The morphological and functional 
control demonstrated by this synthetic nanosystem, coupled with indica-
tions of therapeutic efficacy, constitutes a highly promising platform for 
future clinical application.
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The morphology of functional nanosystems is a key parameter 
in the design of functional nanosystems that are developed for 
therapeutic applications, due to the impact of parameters, such 
as size, shape, and surface chemistry on their performance in 
Adv. Sci. 2019, 6, 1801678
www.advancedsciencenews.com
1801678 (2 of 8) © 2019 The Authors. Published by WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
www.advancedscience.com
polymersomes that possess an, RBC-mimetic, oblate mor-
phology, known as stomatocytes. Such biodegradable stoma-
tocytes possess a unique dual-compartmentalized structure 
that can be exploited in the encapsulation of functional macro-
molecular cargo, which can be utilized as biomimetic reaction 
systems. However, developing this platform as a biomorphic 
nanomedical technology requires careful tailoring in order to 
realize both (multi)functionalization and true stealth-like sur-
face modification.
As a widely described therapeutic application in nano-
medical technologies, photodynamic therapy (PDT) is a key 
strategy in the treatment of solid tumors due to its advanta-
geous performance in anticancer therapy.[6] In contrast to 
traditional chemotherapy/radiation therapies, PDT is noninva-
sive, has low accumulated toxicity, negligible drug resistance, 
and is cost-effective.[7] However, there are key limitations in the 
development of effective PDT therapeutic systems that need 
to be addressed, such as poor solubility of photosensitizers, 
localized hypoxia in the tumor microenvironment, and tumor 
penetration.[8] The issue of hypoxia is particularly pertinent in 
the treatment of tumors where oxygen levels drop steeply from 
the peripheral tissue to the interior and significantly decrease 
PDT efficiency.[9] In order to solve this issue, several hemo-
globin (Hb)-based therapeutic systems have been well devel-
oped.[10] Although these carriers have similar function to RBCs, 
the unique discoidal morphology has remained elusive. With 
such an unusual shape, RBCs are engineered to efficiently 
perform their function of oxygen transport within a complex 
biological environment.[11] Inspired by the challenge to mimic 
the morphology of blood cells and harness this for therapeutic 
applications, we have designed smart compartmentalized nano-
carriers capable of supplying O2 while delivering photoactive 
drugs in order to demonstrate proof-of-principle application in 
PDT. To this end, the development of PEG-PDLLA stomatocytes 
as nanoscopic RBC mimics (nano-RBCs) that can act as oxygen 
carriers for enhanced PDT is an interesting target for the bio-
morphic engineering of therapeutic nanoparticles.
Exploiting the morphology of PEG-PDLLA stomatocytes, we 
demonstrate the coencapsulation of hydrophobic chlorin e6 
(Ce6), a photosensitizer with low dark toxicity and highly effi-
cient generation of singlet oxygen,[12] alongside a reservoir of 
Hb encased in the inner lumen to create nano-RBCs for PDT 
therapy. To provide structural integrity and true stealth char-
acter, we adopt a strategy of camouflaging the particles with 
an erythrocyte-derived cell membrane.[13] Wrapping dual func-
tionalized PEG-PDLLA stomatocytes in a cell membrane allows 
us to preserve the physicochemical properties of the under-
lying architecture while inheriting a complex array of proteins, 
antigens, and other functional moieties, which can facilitate 
effective integration in a biological context.[14] In this paper, 
Adv. Sci. 2019, 6, 1801678
Figure 1. Synthesis and characterization of nano-RBCs. a) Schematic illustration of the fabrication of biodegradable stomatocytes. b) SEM images of 
stomatocytes. Scale bar = 1 µm. The inset SEM image is a single stomatocyte with higher magnification. Scale bar = 100 nm. c) Cryo-TEM image of 
biodegradable stomatocytes. Scale bar = 100 nm. d) SEM image of RBCs which was isolated from mouse whole blood (Balb/c). Scale bar = 10 µm. 
The inset is a SEM image of RBCs with higher magnification. Scale bar = 1 µm. e) UV spectrum of different stomatocyte samples (Empty-S, Hb-S, 
Ce6-S, and Hb/Ce6-S). f) The surface zeta potential (mV) of RBC vesicles, stomatocytes before and after coating with RBC membranes measured by 
DLS. g) Protein concentration of stomatocyte samples before and after coating with the RBC membrane vesicles, measured by a BCA protein assay.
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we therefore present a nanosystem that comprises the funda-
mental features of RBCs while exploiting them as a potential 
PDT therapeutic technology, as demonstrated by 2D cell studies 
and 3D tumor models in vitro.
Biodegradable block copolymers PEG44-PDLLA120 and 
amino-PEG44-PDLLA120 were synthesized by ring-opening 
polymerization as described in previous published work.[15] 
The reaction progress and the obtained products were charac-
terized by nuclear magnetic resonance spectroscopy (Figure S1, 
Supporting Information), differential scanning calorimetry, 
and gel permeation chromatography (Figure S2, Supporting 
Information). Formation of oblate stomatocytes was conducted 
in two steps; first, spherical polymersomes were self-assem-
bled via the solvent switch methodology and then their shape 
transformation was induced under hypertonic (dialysis) condi-
tions, as illustrated in Figure 1a. Stomatocytes were engineered 
with a partial positive surface charge in order to facilitate the 
coating of the particles with an erythrocyte cell membrane, 
which possesses an overall negative potential. Positively 
charged polymersomes were therefore assembled from a solu-
tion of PEG44-PDLLA120 and amino-PEG44-PDLLA120 (9:1 w/w) 
in tetrahydrofuran (THF)/dioxane (1:4 v/v), to which ultrapure 
water was added up to 50 vol% at a rate of 1 mL h−1 with vig-
orous stirring. The cloudy suspension of polymersomes was 
thereafter dialyzed against a NaCl solution of 50 × 10−3 m at 
5 °C to transform spherical polymersomes into oblate stoma-
tocytes (Figure 1b,c).[5] The resulting oblate nanostructures 
bear a striking resemblance to the morphology of RBCs 
(Figure 1d), albeit on a smaller length scale. The characteristic 
dual-compartmental structure of PEG-PDLLA stomatocytes is 
clearly evident from cryogenic transmission electron micros-
copy (cryo-TEM) images. Dynamic light scattering (DLS) data 
indicated that the average hydrodynamic size of the resulting 
nanostructures was 316 nm with a polydispersity index (PDI) 
of 0.06 (Figure S3, Supporting Information).
In order to construct nano-RBCs that mimic the physi-
ological function of RBCs while also possessing the necessary 
photosensitizer for PDT, both Hb and Ce6 were coencapsulated 
in PEG-PDLLA stomatocytes. Empty stomatocytes (Empty-S), 
Hb-loaded stomatocytes (Hb-S), Ce6-loaded stomatocytes 
(Ce6-S), and Hb/Ce6 co-loaded stomatocytes (Hb/Ce6-S) were 
prepared, with visible color changes indicative of successful 
Adv. Sci. 2019, 6, 1801678
Figure 2. Evaluation of singlet oxygen generation. a) Schematic illustration of the detection of 1O2 by measuring the changes in UV–vis spectra 
upon oxidation of ABDA under 660 nm laser irradiation. The time-lapsed absorption spectra of ABDA in the presence of b) Empty-S, c) Ce6-S, and 
d) Hb/Ce6-S. All stomatocytes are coated with an erythrocyte cell membrane. e) Difference in ABDA oxidation as a function of time between Ce6-S 
and Hb/Ce6-S. f) Normalized absorbance changes, including a negative control (Empty-S) and Ce6-S, together with Hb/Ce6-S. Absorbance spectra of 
ABDA in the presence of g) deoxygenated Hb/Ce6-S, h) oxygenated Hb/Ce6-S, and i) normalized absorbance spectra.
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functionalization (Figure S4, Supporting Information). Ce6 
was loaded by dissolving it together with block polymer, and 
the encapsulation of Hb was achieved by addition of the pro-
tein during the shape change process from spherical vesi-
cles to stomatocytes. UV–vis spectra of nano-RBC samples 
were used to quantify the incorporation of both Hb and Ce6 
(Figure 1e), with successful loading of Hb also confirmed by 
sodium dodecyl sulfate-polyacrylamide gel electrophoresis 
(Figure S5, Supporting Information). After having constructed 
loaded stomatocytes, the particle surface was decorated with 
the extracted cell membrane of erythrocytes following literature 
protocols.[16] Briefly, erythrocytes were isolated from the periph-
eral blood of mice (Balb/c, male) and then processed under 
hypotonic conditions to yield vesicles.[17] The morphology of 
RBC vesicular structures (following processing) was confirmed 
using SEM (Figure S6, Supporting Information). Camou-
flaged nano-RBCs were prepared by incubating stomatocytes 
and RBC-derived vesicles under gentle shaking for 4 h. Zeta-
potential measurements confirmed that a charge reversal of the 
positively charged stomatocytes occurred during this process, 
leading to coated nano-RBCs with a zeta potential of ≈ –15 mV 
(Figure 1f). The concomitant increase in detectable protein 
levels in the stomatocyte sample after membrane coating, 
measured using the bicinchoninic acid (BCA) assay, further 
validated the success of this strategy (Figure 1g). A fluorescent 
dye, which associates with the cell membrane, was used to 
visualize this coating, which was indeed clearly observable on 
nano-RBCs using confocal scanning light microscopy (CLSM) 
(Figure S7a, Supporting Information). The corresponding 
morphology and average hydrodynamic size of the resulting 
nano-RBCs were also measured, as shown in Figure S7b,c in 
the Supporting Information. Via biomorphic engineering, we 
were able to fabricate nanoparticles that mimic red blood cells 
in shape, surface properties, and loading (Hb), with further 
synthetic functionalization using a photosensitizer.
To investigate the activity of the photosensitizer, the gen-
eration of singlet oxygen (1O2) was detected using a chemical 
method, whereby 9,10-anthracenediyl-bis(methylene)dimalonic 
acid (ABDA) was employed to react with reactive oxygen spe-
cies (Figure 2a).[18] ABDA consumption (and thereby 1O2 pro-
duction) was monitored by UV–vis spectroscopy (400 nm). 
Empty control samples (Empty-S) showed no 1O2 genera-
tion and ABDA absorbance was stable under laser irradiation 
(Figure 2b). In contrast, samples containing Ce6 only (Ce6-S) 
showed a decreasing ABDA signal indicative of 1O2 genera-
tion, which was even more the case in samples with both Hb 
and Ce6 present (Hb/Ce6-S) (Figure 2c,d). Coencapsulated 
Hb/Ce6-S outperformed Ce6-S samples by ≈40%, which can 
be attributed to the local reservoir of oxygen supplied by Hb 
(Figure 2e,f). Deoxygenation of the nano-RBCs solution showed 
that the performance advantage of the Hb/Ce6-S system could 
be annulled in anoxic conditions; however, upon reoxygenation 
the activity was recovered (Figure 2g–i).
The beneficial effect of the cell membrane modification 
of nano-RBCs was evaluated using mouse macro phage cells 
(RAW 264.7), measuring relative uptake before (Figure S8a, 
Adv. Sci. 2019, 6, 1801678
Figure 3. Systematic circulation time of nano-RBCs evaluated by in vivo fluorescence imaging at designated time points after intravenous injection.
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Supporting Information) and after coating (Figure S8b, 
Supporting Information). After incubation with RAW 264.7 cells, 
the cell uptake efficiency was evaluated as a function of time 
(0, 6, and 12 h) by measuring the fluorescent signal derived 
from Ce6 using flow cytometry. Compared to naked stomato-
cytes (14.6%), only 1.8% of coated nano-RBCs were captured by 
cells after 12 h incubation. This result indicates that nano-RBCs 
inherit the unique antiphagocytic properties of RBCs with sig-
nificantly suppressed cellular uptake; a highly promi sing fea-
ture for a long-circulating delivery system that could be applied 
to cancer therapy. In order to further investigate the systematic 
circulation time of nano-RBCs, in vivo fluorescence imaging 
was conducted. Cyanine 7 (Cy7) was used as a near infrared 
fluorescent dye to label the nano-RBCs. Ex vivo fluorescence 
imaging demonstrated that nano-RBCs were successfully 
labeled with Cy7 (Figure S9a, Supporting Information). BALB/c 
nude mice were divided randomly into three groups, to com-
pare the performance of nano-RBCs, uncoated stomatocytes 
and phosphate-buffered saline (PBS). For each group, 200 µL 
of sample was injected intravenously through the tail vein and 
monitored at different time points Figure 3. The fluorescence 
intensity of the injected particles was furthermore quantitatively 
analyzed (Figure S9b, Supporting Information) It was observed 
that both uncoated stomtocytes and nano-RBCs had long cir-
culation times in vivo, with the coated ones outperforming the 
uncoated stomatocytes, in particular during the first 30 min 
after injection. This demon strates the benefits of both shape 
and surface characteristics for circulation of nanoparticles.
The toxicity of nano-RBCs toward healthy (NIH/3T3) and can-
cerous (HeLa) cell lines was evaluated using an 3-(4,5-dimethyl-
thiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. 
Indeed, low dark toxicity was observed in cell membrane 
coated stomatocytes up to concentrations of 0.25 mg mL−1  
(Figures S10 and S11, Supporting Information). Cytotoxicity 
evaluation of nano-RBCs before cell membrane coating was 
also conducted (Figure S12, Supporting Information), which 
demonstrated that the block polymer used was biocompat-
ible. In vitro PDT efficacy of nano-RBCs was evaluated using 
Adv. Sci. 2019, 6, 1801678
Figure 4. In vitro experiments testing PDT efficacy. a) CLSM images of live/dead assay costained HeLa cells after different treatments (from top to 
bottom: cells only, cells with laser irradiation, Empty-S with laser irradiation, Ce6-S with laser irradiation, and Hb/Ce6-S with laser irradiation. A 660 nm 
laser (0.1 W cm−2) was used to irradiate the different groups for 5 min. Scale bar = 50 µm. b) Flow cytometry of HeLa cells stained with Calcein-AM 
alongside PI for detecting live and dead cells, respectively.
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HeLa cells. After 6 h, cellular uptake was maximal (Figure S13, 
Supporting Information) and intracellular localization of 
nano-RBCs was confirmed by CLSM (Figure S14, Supporting 
Information). Compared to macrophage cells (RAW 264.7, 
Figure S8, Supporting Information), the intracellular content 
of nano-RBCs was much higher in HeLa cells. This is not 
unexpected as for cancerous cells nutrient acquisition, and 
thus endocytosis, is urgently needed to meet the bioenergetic, 
biosynthetic, and redox demands.[19] The cellular uptake 
toward the nano-RBCs was also investigated using different 
types of cell lines; namely, NIH/3T3 (healthy cells) and HepG2 
(cancerous cells). The cellular uptake efficiency was 32% for 
NIH/3T3 cells and 97% for HepG2 cells (Figure S15, Sup-
porting Information).
PDT-induced cytotoxicity was investigated using a 660 nm 
laser (0.1 W cm−2, 5 min) by measuring apoptosis of HeLa 
cells (Calcein-AM as live stain, alongside propidium iodide 
(PI) for dead cells) (Figure 4). Under control conditions (cells 
only), or using laser irradiation without Ce6 present, no cel-
lular apoptosis was observed; however, in the presence of 
either Ce6-S or Hb/Ce6-S significant apoptosis was induced 
after irradiation. Again, the dual functional nano-RBCs were 
most effective and displayed enhanced PDT (Figure S16, 
Supporting Information).
Figure 5. Cell viability under PDT treatment into 3D MCS models as a function of different therapeutic groups. a) Schematic representation of the 
evaluation of PDT treatment using live/dead fluorescent assay. b) From top to bottom, CLSM images of 3D MCSs without irradiation (control group) 
and with laser irradiation in the presence of Empty-S, Ce6-S, and Hb/Ce6-S, respectively. Scale bar = 200 µm. The images on the right row were the 
corresponding integrated fluorescence intensities of each channel (Calcein-AM, PI, and overlay) which were analyzed by ImageJ.
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In order to test the PDT efficacy of the nano-RBCs under 
hypoxic conditions, a multicellular spheroid (MCS) was used as 
3D tumor model.[20] As 3D tumor models better resemble the 
tumor microenvironment, they have been widely used to study 
tumor biology and for screening cancer therapeutics, reducing 
the burden on animal testing.[21] Consequently, MCS com-
prising fibroblasts (NIH/3T3) and breast cancer cells (4T1) were 
created by coculturing the two cell lines in a 5:1 ratio to prepare 
a 3D tumor model as good match for clinical tumor stroma.[22] 
Alongside two control groups (no treatment and laser irradia-
tion) the remaining MSCs were treated with Empty-S, Ce6-S, 
and Hb/Ce6-S samples for 6 h, followed by laser irradiation 
(Figure 5). In line with previous data, control groups did not 
show any apoptosis, highlighting the inherent biocompatibility 
of the PEG-PDDLA stomatocytes. Both Ce6-S and Hb/Ce6-S 
samples showed successful PDT; again this effect was more 
pronounced in nano-RBCs with an internal reservoir of O2. 
These results confirm that nano-RBCs are capable of improving 
PDT efficacy through their capacity to function as an oxygen 
carrier.
Through biomorphic engineering, active PDT therapeutic 
nanoparticles were created that mimicked red blood cells in 
shape, surface properties, oxygen carrier capability, and long 
circulation in vivo. Dual compartmentalized, biodegradable 
PEG-PDLLA stomatocytes, with a shape reminiscent of eryth-
rocytes, were loaded with hemoglobin and the photosensitizer 
Ce6. By coating the surface of these particles with the cell 
membrane of red blood cells, they were given stealth char-
acteristics that shielded them from uptake by macrophages. 
Systematic circulation tests revealed that such nano-RBCs 
displayed a long retention time in vivo. Coencapsulation of 
Hb and Ce6 led to improved PDT performance of nano-RBCs 
both in regular cell culture and a 3D tumor cell model, pro-
viding a mechanism to overcome the kind of hypoxia that 
would be encountered in the tumor microenvironment. Based 
on these observations we think that nano-RBCs constitute 
a highly promising therapeutic platform for future clinical 
applications.
Supporting Information
Supporting Information is available from the Wiley Online Library or 
from the author.
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